{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-008925","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2026-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.989612+00:00","generated_at":"2026-05-16T05:34:08.516300+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sagimet's partner Ascletis reports positive Phase 3 open-label 52-week acne data for denifanstat","bullets":["240 subjects received oral denifanstat 50 mg once daily for up to 40 weeks; 52 weeks total for prior denifanstat patients.","Denifanstat well tolerated: dry eye syndrome (5.5%) and dry skin (5.2%) most common TEAEs; no denifanstat-related SAEs.","No AE-related discontinuations; only 1 grade 1 hair thinning resolved without dose change; no deaths.","All efficacy endpoints (IGA, lesion counts) showed improvements beyond those seen at 12 weeks in the prior Phase 3 trial.","Ascletis holds China rights; Sagimet retains ex-China rights for denifanstat (FASN inhibitor)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-008925","json":"https://secwatch.observer/filing/0001104659-26-008925.json","markdown":"https://secwatch.observer/filing/0001104659-26-008925.md","text":"https://secwatch.observer/filing/0001104659-26-008925.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465926008925/0001104659-26-008925-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465926008925/tm264534d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:34:08.516300+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}